This article contains a pharmacokinetics reference table ("PK cheat sheet") with common cross-species physiological parameters relevant to PK, including animal size, liver blood flow, kidney blood flow, and body volumes. When interpreting compound pharmacokinetic (PK) data, it's helpful to have reference values to compare experimental data to [...]
With increasingly tight timelines between bench and clinic, considering formulation strategies early on can give your program a competitive edge. This succinct formulations guide provides specific clinically-used examples of common formulations, and can help you select a formulation strategy most likely to succeed based on the properties of your compound.
Arvinas’ ARV-471 is an orally bioavailable CRBN-based ER PROTAC degrader for treating patients with ER+/HER2-breast cancer and the first PROTAC to enter Ph. III clinical trials. This molecule one-pager serves as a reference guide, offering an overview of the scientific significance of Arvinas’ ARV-471 program. It includes links to key presentations, publications, patents, preclinical and clinical PK data summaries, and more.
Drug Hunter offers industry professionals a faster way to find and absorb the latest research and insights in drug discovery. It is a curated collection of the most relevant and transferable scientific knowledge so you can spend less time weeding through the noise and more time turning molecules into medicines. But we also love hearing from you, the drug hunters in the field.
Kymera's KT-474 is the first oral heterobifunctional degrader to demonstrate activity in clinical trials outside cancer. This molecule one-pager serves as a reference guide, offering an overview of the scientific significance of Kymera's KT-474 program. It includes links to key presentations, publications, patents, preclinical and clinical PK data summaries, and more.
